Voyager Therapeutics, Inc.: 10-Q filed 2016-08-11
What Voyager Therapeutics, Inc. reported in its quarterly report filed 2016-08-11 (fiscal Q2 2016): 27 published measures, 72 facts as tagged in accession 0001558370-16-007918.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2016-08-11
- Fiscal period
- fiscal Q2 2016
- Accession
- 0001558370-16-007918 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Voyager Therapeutics, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 209,815,000 | USD | |
| At 2015-12-31 | 229,457,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 54,111,000 | USD | |
| At 2015-12-31 | 60,383,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 155,704,000 | USD | |
| At 2015-12-31 | 169,074,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 67,032,000 | USD | |
| At 2015-12-31 | 31,309,000 | USD | |
| At 2015-06-30 | 84,748,000 | USD | |
| At 2014-12-31 | 7,035,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | -9,335,000 | USD | 91 |
| 2016-01-01 to 2016-06-30 | -16,523,000 | USD | 182 |
| 2015-04-01 to 2015-06-30 | -3,895,000 | USD | 91 |
| 2015-01-01 to 2015-06-30 | -18,472,000 | USD | 181 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-06-30 | 657,000 | USD | 182 |
| 2015-01-01 to 2015-06-30 | 650,000 | USD | 181 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | 3,720,000 | USD | 91 |
| 2016-01-01 to 2016-06-30 | 8,550,000 | USD | 182 |
| 2015-04-01 to 2015-06-30 | 4,884,000 | USD | 91 |
| 2015-01-01 to 2015-06-30 | 7,460,000 | USD | 181 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | -66,345,000 | USD | |
| At 2015-12-31 | -49,822,000 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 3,603,000 | USD | |
| At 2015-12-31 | 3,234,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-06-30 | 2,739,000 | USD | 182 |
| 2015-01-01 to 2015-06-30 | 1,204,000 | USD | 181 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | -9,618,000 | USD | 91 |
| 2016-01-01 to 2016-06-30 | -17,085,000 | USD | 182 |
| 2015-04-01 to 2015-06-30 | -3,967,000 | USD | 91 |
| 2015-01-01 to 2015-06-30 | -8,795,000 | USD | 181 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 205,477,000 | USD | |
| At 2015-12-31 | 195,894,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 19,760,000 | USD | |
| At 2015-12-31 | 23,931,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 454,000 | USD | |
| At 2015-12-31 | 612,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | 13,338,000 | USD | 91 |
| 2016-01-01 to 2016-06-30 | 25,635,000 | USD | 182 |
| 2015-04-01 to 2015-06-30 | 8,851,000 | USD | 91 |
| 2015-01-01 to 2015-06-30 | 16,255,000 | USD | 181 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | 10,484,000 | USD | 91 |
| 2016-01-01 to 2016-06-30 | 19,216,000 | USD | 182 |
| 2015-04-01 to 2015-06-30 | 6,455,000 | USD | 91 |
| 2015-01-01 to 2015-06-30 | 11,978,000 | USD | 181 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 25,276,258 | shares | |
| At 2015-12-31 | 24,930,979 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 221,964,000 | USD | |
| At 2015-12-31 | 219,122,000 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 60,000 | USD | |
| At 2015-12-31 | -251,000 | USD |
Other noncurrent liabilities
Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 34,000 | USD | |
| At 2015-12-31 | 44,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 5,049,000 | USD | |
| At 2015-12-31 | 3,430,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 1,484,000 | USD | |
| At 2015-12-31 | 1,557,000 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | -9,305,000 | USD | 91 |
| 2016-01-01 to 2016-06-30 | -16,212,000 | USD | 182 |
| 2015-04-01 to 2015-06-30 | -3,915,000 | USD | 91 |
| 2015-01-01 to 2015-06-30 | -18,492,000 | USD | 181 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | -9,335,000 | USD | 91 |
| 2016-01-01 to 2016-06-30 | -16,523,000 | USD | 182 |
| 2015-04-01 to 2015-06-30 | -6,746,000 | USD | 91 |
| 2015-01-01 to 2015-06-30 | -22,559,000 | USD | 181 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | 2,854,000 | USD | 91 |
| 2016-01-01 to 2016-06-30 | 6,419,000 | USD | 182 |
| 2015-04-01 to 2015-06-30 | 2,396,000 | USD | 91 |
| 2015-01-01 to 2015-06-30 | 4,277,000 | USD | 181 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-06-30 | 288,000 | USD | 182 |
| 2015-01-01 to 2015-06-30 | 276,000 | USD | 181 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-06-30 | -158,000 | USD | 182 |
| 2015-01-01 to 2015-06-30 | -157,000 | USD | 181 |
Inspect the source
- Entity
- Voyager Therapeutics, Inc. / CIK 0001640266
- Captured
- 2026-09-21T17:21:36.313Z
- SEC response SHA-256
8090dbaa25dde9bd5981886fdac01f04bbe6c04ceaca1eba74d87843f38b004e
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001640266.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))